Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative

• DOI: 10.1371/journal.pone.0173121
• Publication Date: 2017-03-10T18:38:35Z
• Authors: Keum-joo Son; Ki ryung Choi; Chung-Kyu Ryu; Seog Jae Lee; Ho Jeong Kim; Hyunah Lee
• Keywords: Immunogenic cell death

Many cancer types are serious diseases causing mortality, and new therapeutics with improved efficacy safety required. Immuno-(cell)-therapy is considered as one of the promising therapeutic strategies for curing intractable cancer. In this study, we tested R2016, a newly developed heterocyclic quinone derivative, induction immunogenic tumor cell death possible novel immunochemotherapeutic. We studied anti-cancer effects R2016 against LLC, lung line B16F10, melanoma line. LLC (non-immunogenic) B16F10 (immunogenic) cells were killed by in dose-dependent manner. reduced viability both inducing apoptosis necrosis, while it demonstrated no cytotoxicity normal splenocytes. Expression markers on surface treated including calreticulin (CRT) heat shock proteins (HSPs) was increased along their genes. Increased CRT expression correlated dendritic (DC) uptake dying cells: proportion CRT+CD11c+cells R2016-treated group. The gene transcription Calr3, Hspb1, Tnfaip6, which related to immunogenicity dead cells, up-regulated cells. On other hand, ANGPT1, FGF7, URGCP levels down-regulated treatment. This data suggests that induced death, an effective anti-tumor immunochemotherapeutic modality.